Loading…
Globe Life
NYSE: GL Financials Insurance 🔎 Screen
S&P 500
🏹 Trader: 🎯 Near 52W High | BRS 64 Forming View all →
$13.9B
Market Cap
9.9
P/E
1.55
PEG
22.6%
ROCE
20.6%
ROE
D/E
26.3%
OPM
-5.6%
% from 52W High
71
α RS
🔍 GL is showing a high-conviction setup because it matches 8 of 37 tracked screener presets, Sector RRG has Financials in the Improving quadrant with the trail still strengthening, and RS Rating is 71. Net: Broad signal stack, not a recommendation. ? Conviction RRG RS Rating
Sources
Conviction 8/37 · Financials in Improving quadrant · RS Rating 71
⚖️ Compare 🔒 Generate Report 🔒 Research Packet 📚 Guides
🌏 Global Investor Returns
Currency-adjusted total returns for GL including FX impact
🌏
Click 🌏 Returns tab to load data
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
📊 Sector Averages
About

Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products to lower middle- and middle-income families in the United States.

Key Ratios Snapshot
📈 Growth Pattern
📊 Quick Scorecard
Loading…
⭐ Superinvestors Holding GL
View All Superinvestors →
Manager Shares Value % of Fund Period
Steve Cohen Point72 Asset Management 42.1K $5.9M 0.01% Mar 2026

SEC Form 13F data. 45-day lag from quarter end.

🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
🎙 Management Tone Confident Specific → Stable 4 quarters Full tone analysis in Intelligence →
📊 MIXED Globe Life Q1 2026: Net operating EPS up 12% to $3.43; full-year guidance $15.40-$15.90
Revenue & Profitability
Q1 2026 net income was $271 million ($3.39 per share) and net operating income was $274 million ($3.43 per share), up 12% from $3.07 a year ago. Life premium revenue grew 3% to $853 million, health premium revenue grew 13% to $417 million. Total premium revenue grew 6%. For full-year 2026, management guides net operating EPS of $15.40-$15.90, representing 8% growth at the midpoint. Share repurchases of $560-$610 million are planned.
Outlook
Management sees resilient demand from its target working-class customers despite macroeconomic pressures such as price inflation. Tailwinds include the continued movement of Medicare beneficiaries from Medicare Advantage to Medicare Supplement, which boosts health sales. Headwinds mentioned include elevated lapse rates in the first year due to economic stress, although renewal persistency remains stable. Management expects the macroeconomic environment to remain supportive for agent recruiting and sales.
Growth Drivers
Key growth levers include agent count expansion: American Income targeting low double-digit growth in 2026, Liberty National and Family Heritage also low double-digit growth. Life sales growth is driven by improved agent productivity (American Income mid-single-digit, Liberty National low double-digit). Health sales growth is driven by Medicare Supplement tailwinds (United American high-teens growth). Direct-to-consumer life sales are expected to grow low single-digit, supported by increased lead generation (5%-10% more leads in 2026).
Balance Sheet & CapEx
Not discussed as a separate capital expenditure line. However, the company invested $419 million in fixed maturities at an average yield of 6.23% and $147 million in commercial mortgage loans and other investments, for a total of $1.1-$1.2 billion expected across all asset classes in 2026 at an average yield of 6.3%-6.5%. Investments in technology and AI are ongoing to improve administrative efficiency and agent productivity.
Margins
Life underwriting margin was 41% of premium in Q1 2026 (same as year-ago). Full-year guidance is 42%-45%, with Q3 expected to reach 49%-54% due to a one-time assumption update benefit of $70-$110 million. Health underwriting margin was 23% of premium in Q1, with full-year guidance of 23%-27%, improving in the last three quarters as rate increases take effect. Administrative expenses were 7.4% of premium in Q1, targeting 7.3% for the full year and below 7% over time via AI efficiency.
Key Risks
Key risks discussed include elevated lapse rates (especially first-year) due to economic stress on policyholders; potential anti-selection in Medicare Supplement (though management downplays it); and interest rate risk from the $1.6 billion net unrealized loss on fixed maturities (though the company has the intent and ability to hold to maturity). Mortality trends have been favorable but could reverse. Agent retention at American Income is a near-term challenge.
Generated by AI · Q1 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter
🔍
🔎 See cross-company document search → ?
📞 Earnings Call Transcripts (5)
Q2 2026 Q2 2026 2026-07-23
Q2 saw strong earnings growth with net income up 20% and net operating income up 10% year-over-year. Premium revenue and investment income rose, while share repurchases and dividends returned significant capital to shareholders. Guidance for 2026 EPS was raised, supported by robust underwriting margins and continued operational momentum.
Q1 2026 Q1 2026 2026-04-23
Q1 saw double-digit net operating income growth, strong premium increases in both life and health, and robust investment income. Guidance was raised for EPS and share repurchases, with AI and technology investments expected to drive further margin expansion and productivity gains.
Q4 2025 Q4 2025 2026-02-05
Net income and operating income rose year-over-year, with strong premium growth in both life and health segments. Guidance for 2026 projects continued premium and EPS growth, supported by technology investments and favorable market trends, while share repurchases remain a capital priority.
Q3 2025 Q3 2025 2025-10-23
Q3 net income and operating income rose sharply year-over-year, with strong premium growth and improved underwriting margins across segments. 2025 guidance calls for continued premium and EPS growth, robust share repurchases, and stable capital metrics, supported by technology investments and favorable mortality trends.
Q2 2025 Q2 2025 2025-07-24
Q2 net operating income rose 10% year-over-year, with strong premium growth in life and health segments and robust agent count expansion. Guidance for 2025 was raised, driven by favorable mortality, improved margins, and technology-driven sales recovery, while a Bermuda reinsurance affiliate is expected to boost future cash flow.
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

Financial Model
Projections are built from each company's audited annual financials (Income Statement, Balance Sheet, Cash Flow) over the last 5 fiscal years. Forward assumptions — revenue growth %, EBITDA margin, D&A (USD millions), interest expense, tax rate, and capex — are AI-generated using historical context and refreshed twice a year: after the December results season and after the September/Q4 results season.

DCF Valuation
Fair Value = Σ(FCFt / (1+WACC)t) + Terminal Value. Terminal Value uses the Gordon Growth Model: FCF5 × (1+g) / (WACC−g). Default WACC: 10% (US risk-free ~4.5%, equity risk premium ~5.5%). Default terminal growth: 3% (long-run US nominal GDP proxy).

CAGR Tracker
Expected 5-year CAGR = (DCF Fair Value / Current Price)1/5 − 1. Assumes fair value is reached in exactly 5 years — a mechanical estimate only.

Data Sources & Limitations
Financial statements sourced from public filings. Prices updated daily. Forward assumptions are AI-generated. All monetary values in USD millions. Non-US ADR companies may have currency conversion inaccuracies. Models are point-in-time and do not update intra-quarter or account for M&A, macro shocks, or extraordinary items.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.